The Therapeutic Effect of the Combination of Edaravone Dexborneol and Butylphthalide in the Treatment of Acute Cerebral Infarction and Its Impact on Neurological Function and Oxidative Stress Indicators in Patients
Objective To explore the effect of the combination therapy of edaravone dexborneol and Butylphthalein on patients with acute cerebral infarction(ACI).Methods 82 ACI patients admitted to Liangshan County People's Hospital from July 2022 to February 2023 were selected as the research subjects,divided into a control group and an observation group using a random number table method,with 41 cases in each group.The control group received treatment with butylphthalide,the observation group received edaravone dexborneol on the basis of the control group.The clinical efficacy,neurological function,cerebral hemodynamic indicators,oxidative stress indicators,and incidence of adverse reactions between two groups were compared.Results After treatment,the total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P＜0.05).After treatment,the National Institutes of Health Stroke Scale scores,malondialdehyde in the observation group were lower than those in the control group,while the minimum blood flow velocity,minimum blood flow,superoxide dismutase,total antioxidand capacity in the observation group were higher than those in the control group,the differences between groups were statistically significant(P＜0.05).There was no statical significance of adverse reactions between two groups(P＞0.05).Conclusion The use of a combination of edaravone dexborneol and butylphthalide can enhance the therapeutic effect of ACI,accelerate the recovery of its neurological function,and significantly regulate cerebral hemodynamics and oxidative stress indicators,with good safety.
NETL
NSTL
万方数据
